References
- Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180–9
- Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002; 30: 886–90
- Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 2003; 88: 4867–73
- Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31: 57–61
- Christgau S, Bitsch-Jensen O, Hanover BN, Gamwell HE, Qvist P, Alexandersen P, et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000; 26: 505–11
- Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10: 229–35
- Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744–55
- Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150–64
- Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001; 98: 12497–502
- Orskov C, Hartmann B, Poulsen SS, Thulesen J, Haare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124: 105–12
- Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 806–15
- Jahnsen J, Falch JA, Mowinckel P, Aadland E, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39: 145–53
- Pironi L, Labate AM, Pertkiewicz M, Przedlacki J, Tjellesen L, Staun M, et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr 2002; 21: 289–96
- Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 370–6
- Holst JJ, Hartmann B, Gottschalck IB, Jeppesen PB, Miholic J, Henriksen DB. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand J Gastroenterol 2007; 42: 814–20
- Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff A, , et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002;37:392–8.
- Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, , et al. Disassociation of bone resorption and formation by GLP-2 A 14-day study in healthy postmenopausal women. Bone 2007;40(3):723–9.
- Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559–63.
- Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, , et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54(9):1224–31.
- Karsdal MA, Holst JJ, Henriksen DB. GLP-2 reduces bone resorption in vitro via the osteoclast GLP-2 receptor. J Bone Mineral Res 2004; 19 Suppl 1:416.